A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection DOI Creative Commons
Michael J. Hawkings, Natasha Marcella Vaselli, Dimitrios Charalampopoulos

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(8), P. 1625 - 1625

Published: July 26, 2023

It is known that SARS-CoV-2 infection can result in gastrointestinal symptoms. For some, these symptoms may persist beyond acute infection, what as 'post-COVID syndrome'. We conducted a systematic review to examine the prevalence of persistent and incidence new illnesses following infection. searched scientific literature using MedLine, SCOPUS, Europe PubMed Central medRxiv from December 2019 July 2023. Two reviewers independently identified 45 eligible articles, which followed participants for various outcomes after The study quality was assessed Joanna Briggs Institute Critical Appraisal Tools. weighted pooled any nature duration 10.8% compared with 4.9% healthy controls. seven studies at low risk methodological bias, symptom ranged 0.2% 24.1%, median follow-up time 18 weeks. also higher future such irritable bowel syndrome, dyspepsia, hepatic biliary disease, liver disease autoimmune-mediated inflammatory coeliac historically SARS-CoV-2-exposed individuals. Our has shown that, limited pool mostly low-quality studies, previous exposure be associated ongoing development functional illness. Furthermore, we show need high-quality research better understand association illness, particularly population enteric infections returns pre-COVID-19-restriction levels.

Language: Английский

Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months DOI Creative Commons
Fatih Karaarslan, Fulya Demircioğlu Güneri, Sinan Kardeş

et al.

Clinical Rheumatology, Journal Year: 2021, Volume and Issue: 41(1), P. 289 - 296

Published: Oct. 29, 2021

Language: Английский

Citations

106
Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID DOI Creative Commons

Jun-Won Seo,

Seong Eun Kim, Yoonjung Kim

et al.

Infection and Chemotherapy, Journal Year: 2024, Volume and Issue: 56(1), P. 122 - 122

Published: Jan. 1, 2024

"Long COVID" is a term used to describe condition when the symptoms and signs associated with coronavirus disease 2019 (COVID-19) persist for more than three months among patients infected COVID-19; this has been reported globally poses serious public health issue. Long COVID can manifest in various forms, highlighting need appropriate evaluation management by experts from fields. However, due lack of clear clinical definitions, knowledge pathophysiology, diagnostic methods, treatment protocols, it necessary develop best standard guidelines based on scientific evidence date. We developed guideline diagnosing treating long analyzing latest research data collected start COVID-19 pandemic until June 2023, along consensus expert opinions. This provides recommendations diagnosis that be applied practice, total 32 key questions related COVID. The should comprehensive, including medical history, physical examination, blood tests, imaging studies, functional tests. To reduce risk developing COVID, vaccination antiviral during acute phase are recommended. will revised there reasonable updates availability new

Language: Английский

Citations

24
Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: a multicenter study DOI
César Fernández‐de‐las‐Peñas, Ana I. de‐la‐Llave‐Rincón, Ricardo Ortega‐Santiago

et al.

Pain, Journal Year: 2021, Volume and Issue: 163(9), P. e989 - e996

Published: Dec. 10, 2021

Abstract This study investigated the prevalence of long-term musculoskeletal post-COVID pain and their risk factors in a large cohort COVID-19 survivors. A multicenter including patients hospitalised because 5 hospitals Madrid (Spain) during first wave pandemic was conducted. Hospitalisation clinical data were collected from medical records. Patients scheduled for telephone interview after hospital discharge collecting about pain. Anxiety/depressive levels sleep quality likewise assessed. From 2000 recruited, total 1969 individuals (46.4% women, age: 61 years, SD: 16 years) assessed on average at 8.4 (SD: 1.5) months discharge. At time study, 887 (45% women) reported According to presence previous symptoms, “de novo” (new-onset) 74.9%, whereas 25.1% experienced an increase symptoms (exacerbated COVID-related pain). Female sex (odds ratio [OR]: 1.349, 95% confidence interval [CI]: 1.059-1.720), history (OR 1.553, CI 1.271-1.898), myalgia 1.546, 1.155-2.070) headache (1.866, 1.349-2.580) as COVID-19–associated onset days 1.013, 1.004-1.022) associated with In conclusion, is present 45.1% survivors 8 most developing de novo sex, pain, acute phase,

Language: Английский

Citations

90
Musculoskeletal symptoms and related factors in postacute COVID‐19 patients DOI Open Access
Fulya Bakılan, İsmail Güneş Gökmen, Burcu Ortanca

et al.

International Journal of Clinical Practice, Journal Year: 2021, Volume and Issue: 75(11)

Published: Aug. 13, 2021

There is a lack of an overview the factors associated with postacute COVID-19 musculoskeletal symptoms. The aims this study were as follows: 1- to evaluate most frequent admission symptoms and frequency in patients; 2- determine related symptoms.A total 280 patients (183 females, 97 males) enrolled divided into two groups: whose initiated or aggravated by (n = 240); did not change 40). variables demographic treatment data, on admission, symptoms, laboratory results (complete blood count, erythrocyte sedimentation rate, C-reactive protein, ferritin d-dimer), chest computed tomography findings during acute COVID-19.Most have fatigue (71.8%), spine pain (70.7%) myalgia (60.7%). common region was back (30.4%). dyspnoea 30%, cough 18.5% 10.7%. Having any chronic disease (P .031), duration hospital stay .016), .018), d-dimer .035) levels significantly higher, lymphocyte .024) lower began COVID-19.Back symptom admission. fatigue, myalgia. Lower higher levels, presence infection, having diseases post-COVID-19

Language: Английский

Citations

70
Reactive arthritis after COVID-19: a case-based review DOI Creative Commons
Burhan Fatih Koçyiğit, Ahmet Akyol

Rheumatology International, Journal Year: 2021, Volume and Issue: 41(11), P. 2031 - 2039

Published: Sept. 22, 2021

Language: Английский

Citations

69
Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis DOI Creative Commons
Arup Choudhury, Raseen Tariq, Anuraag Jena

et al.

Therapeutic Advances in Gastroenterology, Journal Year: 2022, Volume and Issue: 15, P. 175628482211184 - 175628482211184

Published: Jan. 1, 2022

Prolonged symptoms after COVID-19 are an important concern due to the large numbers affected by pandemic.To ascertain frequency of gastrointestinal (GI) manifestations as part long GI COVID.A systematic review and meta-analysis studies reporting in COVID was performed.Electronic databases (Medline, Scopus, Embase, Cochrane Central Register Controlled Trials, Web Science) were searched till 21 December 2021 identify COVID. We included overall or individual excluded pediatric those not providing relevant information. calculated pooled various all patients with also using inverse variance approach. All analysis done R version 4.1.1 packages 'meta' 'metafor'.A total 50 included. The frequencies 0.12 [95% confidence interval (CI), 0.06-0.22, I2 = 99%] 0.22 (95% CI, 0.10-0.41, 97%) COVID, respectively. abdominal pain, nausea/vomiting, loss appetite, taste 0.14 0.04-0.38, 96%), 0.06 0.03-0.11, 98%), 0.20 0.08-0.43, 0.17 0.10-0.27, 95%), respectively, COVID-19. diarrhea, dyspepsia, irritable bowel syndrome 0.10 0.04-0.23, 0.06-0.50, 97%), 0.06-0.37, respectively.GI seen 12% 22% Loss syndrome, taste, pain five most common Significant heterogeneity small number for some analyses limitations review.

Language: Английский

Citations

66
Effects of COVID-19 on the Musculoskeletal System: Clinician’s Guide DOI Creative Commons
Laith K. Hasan,

Brittney Deadwiler,

Aryan Haratian

et al.

Orthopedic Research and Reviews, Journal Year: 2021, Volume and Issue: Volume 13, P. 141 - 150

Published: Sept. 1, 2021

Abstract: The global pandemic caused by SARS-CoV-2, or COVID-19, continues to impact all facets of daily life. Clinical manifestations COVID-19 commonly include musculoskeletal symptoms such as myalgias, arthralgias, and neuropathies/myopathies. inflammatory response its on the respiratory system have been focus most studies. However, literature is more limited regarding implications for other organ systems, specifically system. Previous studies described how systemic inflammation may play a role in bone joint pathology. Furthermore, it important understand effects current therapeutics used treatment In this study, we will review understanding effect has system, provide an overview patients infected with virus, address key issues clinicians during care patients. Keywords: SARS-CoV-2

Language: Английский

Citations

62
Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis DOI Creative Commons
Bang Zheng, Luke Daines, Qing Han

et al.

European Respiratory Review, Journal Year: 2022, Volume and Issue: 31(166), P. 220071 - 220071

Published: Nov. 2, 2022

Persistent breathlessness >28 days after acute COVID-19 infection has been identified as a highly debilitating post-COVID symptom. However, the prevalence, risk factors, mechanisms and treatments for remain poorly understood. We systematically searched PubMed Embase relevant studies published from 1 January 2020 to November 2021 (PROSPERO registration number: CRD42021285733) included 119 eligible papers. Random-effects meta-analysis of 42 872 patients with reported in 102 papers found an overall prevalence 26% (95% CI 23-29) when measuring presence/absence symptom, 41% 34-48) using Medical Research Council (MRC)/modified MRC dyspnoea scale. The pooled decreased significantly 1-6 months 7-12 post-infection. Post-COVID was more common those severe/critical infection, who were hospitalised females, less likely be by Asia than Europe or North America. Multiple pathophysiological have proposed (including deconditioning, restrictive/obstructive airflow limitation, systemic inflammation, impaired mental health), but body evidence remains inconclusive. Seven cohort one randomised controlled trial suggested rehabilitation exercises may reduce breathlessness. There is urgent need mechanistic research development interventions prevention treatment

Language: Английский

Citations

60
The COVID‐19 pandemic and its consequences for chronic pain: a narrative review DOI Open Access
Harsha Shanthanna, Ariana M. Nelson, Narayan R. Kissoon

et al.

Anaesthesia, Journal Year: 2022, Volume and Issue: 77(9), P. 1039 - 1050

Published: July 18, 2022

Summary The COVID‐19 pandemic transformed everyday life, but the implications were most impactful for vulnerable populations, including patients with chronic pain. Moreover, persistent pain is increasingly recognised as a key manifestation of long COVID. This narrative review explores consequences Publications identified related to influence on burden pain, development new‐onset because COVID proposed mechanisms and vaccines interventions. Broadly, underlying due SARS‐CoV‐2 infection could be caused by ‘systemic inflammatory‐immune mechanisms’, ‘direct neuropathic mechanisms’ or ‘secondary viral treatment’. Existing populations variably impacted social determinants health appeared degree effect. increased absolute numbers headache. In acute phase, headache presenting symptom predicted milder course. New‐onset was reportedly common likely involves multiple mechanisms; however, its prevalence decreases over time symptoms appear fluctuate. Patients requiring intensive support particularly susceptible symptoms. Some evidence suggests steroid exposure (often used interventions) may affect vaccine efficacy, there no clinical repercussions date. Although existing management help symptomatic relief, need advance research focusing mechanism‐based treatments within domain multidisciplinary care.

Language: Английский

Citations

56
DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study DOI

Michael Di Iorio,

Claire Cook,

Kathleen M.M. Vanni

et al.

Seminars in Arthritis and Rheumatism, Journal Year: 2022, Volume and Issue: 55, P. 152025 - 152025

Published: May 19, 2022

Language: Английский

Citations

54